Brink N S, Chopra R, Perrons C J, Ring C J, Garson J A, Briggs E M, Goldstone A H, Linch D C, Tedder R S
Department of Medical Microbiology, University College and Middlesex School of Medicine, London.
Br J Haematol. 1993 Mar;83(3):498-503. doi: 10.1111/j.1365-2141.1993.tb04677.x.
Patients receiving multiple transfusions are at risk of acquiring hepatitis C (HCV) infection from a donor population which is unscreened for hepatitis C antibodies (anti-HCV). Prior to the introduction of blood donor screening for anti-HCV in the U.K., a group of patients undergoing therapy for haematological malignancies, with repeatedly abnormal liver function tests, were investigated for acute HCV infection. Thirty-two patients had repeatedly raised serum transaminases, and eight of these (25%) had evidence of an acute HCV infection. The diagnosis was made by the detection of HCV-RNA in the patients' serum using a complementary DNA/polymerase chain reaction (cDNA/PCR) procedure. All eight patients had received myeloablative chemotherapy and three had undergone bone marrow transplantation. HCV infection contributed significantly to the morbidity of this group of patients in the short term whilst they were undergoing treatment for their underlying haematological condition. The long-term effects have yet to be evaluated. In an attempt to decrease hepatic damage due to HCV, three patients were placed on interferon therapy. None showed a sustained reduction in serum transaminases or HCV viraemia. It is hoped that the introduction of anti-HCV screening of blood donors, will reduce the frequency of transfusion-acquired HCV infections. Early observations suggest that this is the case, as we have seen no new cases of HCV infection in our unit since the introduction of donor screening in September 1991.
接受多次输血的患者有从未进行丙型肝炎抗体（抗 - HCV）筛查的供血人群中感染丙型肝炎病毒（HCV）的风险。在英国引入对献血者进行抗 - HCV筛查之前，对一组正在接受血液系统恶性肿瘤治疗且肝功能检查反复异常的患者进行了急性HCV感染调查。32名患者血清转氨酶反复升高，其中8名（25%）有急性HCV感染的证据。诊断通过使用互补DNA/聚合酶链反应（cDNA/PCR）程序检测患者血清中的HCV - RNA来进行。所有8名患者均接受了清髓性化疗，3名患者接受了骨髓移植。在这组患者接受基础血液系统疾病治疗的短期内，HCV感染对其发病率有显著影响。其长期影响尚未评估。为了减少HCV引起的肝损伤，3名患者接受了干扰素治疗。但无一例患者血清转氨酶或HCV病毒血症持续降低。希望引入对献血者的抗 - HCV筛查能降低输血获得性HCV感染的频率。早期观察表明情况确实如此，自1991年9月引入献血者筛查以来，我们科室未发现新的HCV感染病例。
